Brief: Larimar Therapeutics Q2 Net Income USD -8.366 Million
Aug 10 (Reuters) - Larimar Therapeutics Q2 operating expenses USD 9.62 million. * Q2 income from operations USD -9.62 million * Q2 basic EPS USD -0.19
Recent news on Larimar Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Larimar tumbles as safety concerns resurface in rare disease drug study update
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-SpaceX, Charter, Gulfport Energy
Larimar tumbles as safety concerns resurface in rare disease drug study update